VRDN Stock Price
Viridian Therapeutics, Inc.
VRDN stock price is $17.86 (-2.30% on the day), giving Viridian Therapeutics, Inc. a market cap of $2.07B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
VRDN Stock Overview
- Price
- $17.86
- Previous close
- $18.28
- Open
- $18.02
- Market cap
- $2.07B
- P/E ratio
- -6.0
- 52-week range
- $13.18 - $34.29
- 1-year price target
- $36.88
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSC
- MarketXLS Rank
- 46
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also offers VRDN-006 that is in Phase 1 clinical trial and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRDN | $17.86 | -2.3% | 317.03K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Viridian Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW